• Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Interview: Delay in Second-line T2D Treatment Among Younger US Veterans Sparks Investigator Concern


In a new study of nearly 200 000 US adutls with type 2 diabetes (T2D) in the US Department of Veterans Affairs health system, a Colorado-based research team observed progressive delays in initiation of second-line therapy, increases in hyperglycemia level at time of treatment intensification, and a reduction in rates of guideline-recommended HbA1c surveillance during the first 5 years after a diabetes diagnosis, a set of trends, the investigators say, that points to inreasing thereapeutic inertia in the critical early phase of treatment for T2D.

In a recent interview with Patient Care, lead study author Sridharan Raghavan, MD, PhD, details the results that he and his team found most concerning, including the temporal trend in younger individuals for whom mean HbA1c was >9% at initiation of second-line treatment.

For more of Patient Care's conversation with Dr Raghavan, please see:

Sridharan Raghavan, MD, PhD is an assitant professor and clinical investigator in the division of hosptial medicine, University of Colorado Denver, Anschutz Medical Campus and a clinician at the Rocky Mountain Regional Veterans Affairs Medical Center in Aurora, Colorado.

Reference: Raghavan S, Warsavage T, Liu WG, et al. Trends in timing of and glycemia at initiation of second-line type 2 diabetes treatment in US adults. Diabetes Care. Published online ahead of print March 28, 2022;dc212492.

Related Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Related Content
© 2024 MJH Life Sciences

All rights reserved.